Pseudomonas aeruginosa is the leading cause of nosocomial infections with high mortality rates owing to the limited therapeutic options for multidrug-resistant Pseudomonas aeruginosa (MDRPA) and metallo-beta-lactamase (MBL)-producing strains. Herein, we present a meta-analysis exploring the association between MDRPA and São Paulo MBL-1 (SPM-1)-producing strains vs. mortality. Online databases were screened to identify studies published between 2006 and 2016. A total of 15 studies, comprising 3,201 cases of P. aeruginosa infection, were included. Our results demonstrated a higher mortality rate among patients infected with MDRPA (44.6%, 363/813) than those with non-MDRPA infection (24.8%, 593/2,388) [odds ratio (OR) 2.39, 95% confidence interval (CI) 1.70-3.36, p <0.00001]. The risk of mortality in patients with non-SPM-1 strains was four times higher than that observed in the patients of the SPM-1 group; however, no statistically significant difference was observed (p = 0.43). In conclusion, the results of our study demonstrated that patients infected with MDRPA had a significantly higher mortality rate than that of patients infected with non-MDRPA strains, especially patients with bloodstream infection (BSI), immunosuppression, and inadequate antimicrobial therapy. The absence of studies on the molecular aspects of blaSPM-1 and its association with mortality limited the analysis; therefore, our results should be interpreted with caution. Our findings also highlight the need for more studies on the molecular aspects of resistance and the peculiarities of different nosocomial settings.
INTRODUCTION
Pseudomonas aeruginosa is a versatile pathogen responsible for nosocomial infections with high mortality rates in critically ill patients, including those from general wards and outpatient clinics [1] [2] [3] [4] . In recent decades, publications worldwide have highlighted the increasing issue of carbapenem and antipseudomonal broad-spectrum cephalosporin resistance 1, 5, 6 . The effect of bacterial resistance is directly related to infection severity and underlying disease, as well as the selected antibiotic therapy. Furthermore, the complexity of resistance mechanisms has contributed to a gradual increase in resistance rates, which are of particular concern in nosocomial settings 3, 7, 8 .
Among the multiple resistance mechanisms in P. aeruginosa, including activation and overexpression of efflux systems and alteration of outer membrane permeability, the production of metallo-beta-lactamases (MBL), which can hydrolyze almost all beta-lactam agents, is one of the most important ones as it severely limits therapeutic options. Moreover, it also has been associated with prolonged hospitalization, polymicrobial infections, previous antibiotic use, and inadequate therapy [8] [9] [10] .
So far, 10 major clinically important MBL groups have been identified, including Imipenemase-type metallo-ß-lactamase (IMP), Verona integron-encoded metallo-ß-lactamases, (VIM), São Paulo metallo-ß-lactamase (SPM), Germany imipenemase (GIM), Seoul imipenemase (SIM), New Delhi metallo-ß-lactamase (NDM), Kyorin Health Science metallo-ß-lactamase (KHM), Tripoli metallo-ß-lactamase (TMB), Dutch imipenemase (DIM) and Florence imipenemase (FIM). These MBL variants quickly spread across Europe, then to North America, Latin America, Asia, and Oceania, reflecting a problem of global dimensions 5, 6, 11, 12 . A relevant aspect regarding this fast dissemination of resistance traits among P. aeruginosa strains is related to the fact that the resistance genotype may be transferred through mobile genetic elements. The emergence of multidrug-resistant (MDR) strains demonstrates the need for changes in routine laboratory diagnostic procedures, such as the incorporation of the molecular detection of bla-variant genes, particularly blaSPM-1, which is the most prevalent variant in Brazil [13] [14] [15] . Studies included in the meta-analysis (15) Excluded articles by title, abstract and duplication (n= 2,077)
Excluded articles due absence of information on mortality or MDR (n= 480)
Excluded articles not meeting all the inclusions criteria (n=105)
Several studies have reported confl icting results regarding mortality associated with multidrug-resistant Pseudomonas aeruginosa (MDRPA) infections, and few reports have highlighted this association with MBL-producing strains 7, 8, 10, 16, 17 . Therefore, the present meta-analysis evaluated the association of MDR, the presence of the blaSPM-1 gene, and the risk of mortality in patients with P. aeruginosa infection.
METHODS

Search strategy and inclusion criteria
The studies were analyzed based on the essential standards listed in the 2011 Cochrane Handbook for Systematic Review of Intervention, edited by Higgin and Green 18 . A search of the PubMed, MEDLINE, BIREME, and Embase databases was conducted using the following keywords and combinations thereof: Pseudomonas aeruginosa, P. aeruginosa, multidrugresistance, MDR, non-multidrug-resistance, non-MDR, blaSPM-1 gene, and mortality. The articles were examined by two investigators and studies published in English, Portuguese, and/or Spanish between 2006 and 2016 were included. Studies including (I) humans, (II) at least one group of comparison to MDRPA, and (III) mortality evaluation and antimicrobial resistance were included in the analysis. Unpublished articles (abstracts) or articles that did not fi t these criteria were excluded from analysis.
Data extraction and quality assessment
The data were extracted by two investigators. Information such as author, study period, study design, country, setting, defi nitions of mortality, mortality by MDRPA and non-MDRPA, and site of infection were extracted from each study, as well as whether the study authors had controlled for confounding clinical and demographic factors.
Defi nition of MDR
Multidrug-resistant was defi ned as resistance to at least three different classes of antimicrobials, including carbapenems (imipenem, meropenem), antipseudomonal cephalosporins (ceftazidime and cefepime), fl uoroquinolones (ciprofl oxacin), aminoglycosides (gentamicin and amikacin), and β-lactams with inhibitors (piperacillin-tazobactam).
Data analysis
Statistical analyses were performed by calculating the odds ratios (ORs) with the Mantel-Hansel test at 95% confi dence interval (CI) and 5% signifi cance level (p ≤ 0.05) to compare patients infected by MDRPA and non-MDRPA strains. Forest plots were produced using Review Manager 5.0 19 . Figure 1 , a total of 2,677 articles were retrieved, 2,077 of which were excluded after title and abstract evaluation, as well as because of duplication. In the second screening, 480 studies were excluded for their lack of information related to mortality and MDR and/or MBL detection; the remaining 120 articles were fully evaluated by the investigators. Finally, 15 studies matching the inclusion criteria were selected for analysis. The main characteristics of the 15 studies included in the metaanalysis are summarized in Table 1 . The articles were published between 2006 and 2016, with a sample size comprising 3,201 P. aeruginosa isolates from five countries. Most of the studies were retrospective in design. The main sample source was bloodstream infection (BSI) and 30-day mortality was the outcome of interest.
RESULTS
As shown in
The meta-analysis illustrated in Figure 2 revealed a higher proportion of deaths among patients with MDRPA (44.65%, 363/813) compared to that in patients with non-MDRPA infections (24.8%, 593/2,388) (OR 2.39, 95% CI 1.70-3.36, p <0.00001). Despite the substantial statistical heterogeneity (I 2 = 66%), only the study by Peña 20 presented results in favor of the non-MDRPA group; however, their results were not statistically significant (OR 0.82, 95% CI 0.35-1.97), which was possibly because they used the severity of the acute illness as the main predictor for mortality rather than the presence of an MDR isolate.
As presented in Figure 3 , the risk of mortality in the non-SPM-1 group was four times greater than that observed in the SPM-1 group. However, the difference was not statistically significant (p = 0.43), and there was great heterogeneity between the studies (I 2 = 82%) caused by Gomes 2 as a result of clinical and methodological differences among the investigations. 
DISCUSSION
This study selected several original articles for analysis, combining and performing a synthesis of the results based on variables associated with MDRPA and relating them to mortality. The meta-analysis of the data revealed that P. aeruginosa infections resulted in high mortality rates in cases of infection with MDRPA compared to those of non-MDRPA infections. P. aeruginosa infections are opportunistic and are considered to have a high mortality in a global context. This pathogen is closely related to nosocomial infections in critically ill patients, but it also affects immunocompetent individuals 3,20-22 .
Most of the selected studies focused on the bloodstream as the main site of infection. BSIs increase the costs to the hospital and the complexity of cases; they may prolong hospitalization and are often exacerbated by unfavorable outcomes. A study conducted at the teaching hospital in Pará State, Northern Brazil identifi ed BSI as the most frequent route of infection among inpatients in intensive care units (ICU) 10 . A similar scenario was reported in India, wherein 48.2% of 593 blood cultures was determined to be positive for P. aeruginosa, 63.6% of which were MDR; this also highlights the increasing occurrence of MBL in the region, representing a major therapeutic problem 23 .
Among the selected works, none assessed neonatal inpatients exclusively. Considering the peculiarity of the neonatal ICU population, there were few reports in the literature regarding the behavior of these resistant microorganisms. Life support of these patients requires both direct and indirect special care, aside from presenting critical immunosuppression and possible prolonged hospitalization 24 . However, a study conducted in 12 hospital centers of hematology and oncology in Italy described a retrospective series of nine years of BSI with P. aeruginosa in children diagnosed with cancer in pediatric oncology. The mortality rate reported in this study was 35.9% in cases of infection with MDRPA. This investigation emphasized that infection with this pathogen is a major concern in patients undergoing chemotherapy despite empirical antibiotic therapy containing at least one active drug, and that multidrug resistance is the greatest risk factor for a fatal outcome 25 .
Although heterogeneous, the studied populations presented common aspects, including immunosuppression, underlying disease, use of immunosuppressive agents, antimicrobial therapy, inadequate empirical therapy, use of invasive procedures, and patient age range. Aside from infection with MDRPA, the main clinical features observed in the studies were HIV-positive patients with various complications, hematologic malignancy, cystic fibrosis, use of mechanical ventilation, and neonatal patients. The test of inconsistency showed a partial heterogeneity (I 2 = 66%) between studies 2,3,26-29 .
Zavascki et al. 8 reported that patients with infections by MBL-producing P. aeruginosa have higher mortality rates than those infected with non-MBL-producing strains, emphasizing the importance of appropriate initial antimicrobial therapy to reduce mortality rates. Exposure to antimicrobial agents predisposes patients to infection by MDRPA strains, and this selective pressure has contributed to the increase and spread of this pathogen, as well as the expression of different resistance genes 3, 5, 8, 12, 13 .
The data in Figure 3 show controversial results regarding the risk of death among patients infected with SPM-1producing strains, as seen in the three studies that investigated this aspect 2,10,21 . Our database search identified many studies that lacked information regarding the detection of MBL (blaSPM-1) and mortality, preventing a more concrete analysis; with the increasing prevalence of SPM-1-producing strains in different regions, particularly in Brazil, this demonstrates the need for investigations with representative sample sizes for analysis 5, 8, 10, 14, 15 .
In conclusion, the results of our study indicate a significantly higher mortality among patients infected with MDRPA compared to those infected with non-MDRPA, especially patients with BSI, immunosuppression, and inadequate antimicrobial therapy. However, the lack of published studies on the molecular aspects of blaSPM-1 detection limited the analysis and its association with mortality; therefore, our results should be interpreted with caution. Heterogeneity of the populations from the studies in this meta-analysis was observed because of the particular characteristics of each setting, especially for the condition of immunosuppression caused by different co-morbidities. Our findings highlight the need for additional studies on the molecular aspects of resistance and the peculiarities of different nosocomial settings.
